Page 234 - 82_ex2

61. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical
efficacy of orlistat therapy in overweight and obese
patients with insulin-treated type 2 diabetes: a 1-year
randomized controlled trial. Diabetes Care 2002; 25:
1033-41.
62. Miles JM, Leiter L, Hollander P, et al. Effect of
orlistat in overweight and obese patients with type 2
diabetes treated with metformin. Diabetes Care 2002;
25: 1123-8.
63. Lindgarde F. The effect of orlistat on body weight and
coronary heart disease risk profile in obese patients:
the Swedish Multimorbidity Study. J Intern Med
2000; 248: 245-54.
64. Padwal R, Kezouh A, Levine M, Etminan M. Long-
term persistence with orlistat and sibutramine in a
population-based cohort. Int J Obes (London) 2007;
31: 1567-70.
65. Cavaliere H, Floriano I, Medeiros-Neto G.
Gastrointestinal side effects of orlistat may be
prevented by concomitant prescription of natural
fibers (psyllium mucilloid) Int J Obes Relat Metab
Disord 2001; 25: 1095-9.
66. XENICAL - orlistat capsule. 2016. Disponible en
http://www.gene.com/download/pdf/xenical_prescribi
ng.pdf. Acceso el 3 de marzo de 2016.
67. Kopelman P, de Groot HG, Rissanen A, et al. Weight
loss, HbA1c reduction, and tolerability of cetilistat in
a randomized, placebo-controlled phase 2 trial in
obese diabetics: comparison with orlistat (Xenical).
Obesity 2010; 18: 108-15.
68. Astrup A, Carraro R, Finer N, et al. Safety, tolerability
and sustained weight loss over 2 years with the once-
daily human GLP-1 analog, liraglutide. Int J Obes
(Lond) 2012; 36: 843-54.
69. Linnebjerg H, Kothare PA, Skrivanek Z, et al.
Exenatide: effect of injection time on postprandial
glucose in patients with Type 2 diabetes. Diabetic
Med 2006; 23: 240-5.
70. Amori RE1, Lau J, Pittas AG. Efficacy and safety of
incretin therapy in type 2 diabetes: systematic review
and meta-analysis. JAMA 2007; 298: 194-206.
71. Blonde L, Russell-Jones D. The safety and efficacy of
liraglutide with or without oral antidiabetic drug
therapy in type 2 diabetes: an overview of the LEAD
1-5 studies. Diabetes Obes Metab 2009; 11(Suppl. 3):
26-34.
72. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of
exenatide and lifestyle modification on body weight
and glucose tolerance in obese subjects with and
without prediabetes. Diabetes Care 2010; 33: 1173-5.
73. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-
1: exenatide once weekly produces sustained glycemic
control and weight loss over 52 weeks. Diabetes Care
2010; 33: 1255-61.
74. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman
MS, Baron AD. Effects of exenatide (exendin-4) on
glycemic control and weight over 30 weeks in
224
Juan Tamargo
metformin-treated patients with type 2. Diabetes Care
2005; 28: 1092-1100.
75. Wadden TA, Hollander P, Klein S, et al. Weight
maintenance and additional weight loss with
liraglutide after low-calorie-dietinduced weight loss:
the SCALE Maintenance randomized study. Int J
Obes (Lond) 2013; 37: 1443-51.
76. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE,
Saris WHM. Effects of the once-daily GLP-1 analog
liraglutide on gastric emptying, glycemic parameters,
appetite and energy metabolism in obese, nondiabetic
adults. Int J Obes (Lond) 2014; 38: 784-93.
77. Garber A, Henry R, Ratner R, et al. Liraglutide versus
glimepiride monotherapy for type 2 diabetes (LEAD-3
Mono): a randomised, 52-week, phase III, double-
blind, parallel-treatment trial. Lancet 2009; 373: 473-
81.
78. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE
Obesity and Prediabetes NN8022-1839 Study Group.
A Randomized, Controlled Trial of 3.0 mg
of Liraglutide in Weight Management. N Engl J Med
2015; 373: 11-22.
79. Zhang Y, Proenca R, Maffei M, Barone M, Leopold
L, Friedman JM. Positional cloning of the mouse
obese gene and its human homologue. Nature 1994;
372: 425-32.
80. Licinio J, Caglayan S, Ozata M, et al. Phenotypic
effects of leptin replacement on morbid obesity,
diabetes mellitus, hypogonadism, and behavior in
leptin-deficient adults. Proc Natl Acad Sci U S A
2004; 101: 4531-6.
81. Heymsfield SB1, Greenberg AS, Fujioka K et al.
Recombinant leptin for weight loss in obese and lean
adults: a randomized, controlled, dose-escalation trial.
JAMA 1999; 282: 1568-75.
82. Asakawa A, Inui A, Yuzuriha H, et al.
Characterization of the effects of pancreatic
polypeptide in the regulation of energy balance.
Gastroenterology 2003; 124: 1325-36.
83. Gantz I, Erondu N, Mallick M, et al. Efficacy and
safety of intranasal peptide YY3-36 for weight
reduction in obese adults. J Clin Endocrinol Metab
2007; 92: 1754-7.
84. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E,
Charles MA. Effects of 1-year treatment with
metformin on metabolic and cardiovascular risk
factors in non-diabetic upper-body obese subjects with
mild glucose anomalies: a post-hoc analysis of the
BIGPRO1 trial. Diabetes Metab 2009; 35: 385-91.
85. Gadde KM, Allison DB. Combination pharmaceutical
therapies for obesity. Expert Opin Pharmacother 2009;
10: 921-5.
86. Kaya A, Aydin N, Topsever P, et al. Efficacy of
sibutramine, orlistat and combination therapy on
short-term weight management in obese patients
Biomed Pharmacother 2004; 58: 582-7.
@Real Academia Nacional de Farmacia. Spain